ELANCO UK AH LIMITED
Operating as a UK subsidiary of the New York Stock Exchange-listed Elanco Animal Health Incorporated, the company distributes veterinary pharmaceuticals and health products for farm animals and pets.
Get an alert when ELANCO UK AH LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£35M
+61.8% vs 2023
Net assets
£121M
+5.9% vs 2023
Employees
331
+21.7% vs 2023
Profit before tax
£9.2M
-32.1% vs 2023
Net assets
2-year trend · vs Health Care median
Accounts
2-year trend · Δ = latest vs prior filed period · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 | Δ vs prior |
|---|---|---|---|---|
| Turnover | £331,449,000 | £342,988,000 | +3.5% | |
| Operating profit | £16,740,000 | £11,798,000 | -29.5% | |
| Profit before tax | £13,535,000 | £9,195,000 | -32.1% | |
| Net profit | £9,598,000 | £5,582,000 | -41.8% | |
| Cash | £21,691,000 | £35,097,000 | +61.8% | |
| Total assets less current liabilities | £114,933,000 | £122,240,000 | +6.4% | |
| Net assets | £114,005,000 | £120,699,000 | +5.9% | |
| Equity | £114,005,000 | £120,699,000 | +5.9% | |
| Average employees | 272 | 331 | +21.7% | |
| Wages | £22,621,000 | £28,298,000 | +25.1% | |
| Directors' remuneration | £557,000 | £580,000 | +4.1% |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | 5.1% | 3.4% | |
| Net margin | 2.9% | 1.6% | |
| Return on capital employed | 14.6% | 9.7% | |
| Current ratio | 1.55x | 1.89x | |
| Interest cover | 3.80x | 3.31x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Ernst & Young
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The directors have assessed the ability of Elanco Animal Health Incorporated to provide the level of support that might be required and see no reason to believe that a material uncertainty exists that may cast significant doubt about the ability of Elanco UK AH Limited to continue as a going concern. On the basis of their assessment of the company's financial position, the Company's Directors have a reasonable expectation that the company will be able to continue in operational existence for the foreseeable future.”
Group structure
- ELANCO UK AH LIMITED · parent
- Dista Products Limited 100%
- Elanco Europe Limited 100%
- Vericore Limited 100%
- Elanco Animal Health UK Limited 100%
- Elanco Animal Vaccines Limited 100%
Significant events
- “In July 2024, Elancó globally completed the sale of its Aqua portfolio to Merck for $1.3bn, the proceeds of which contributed to debt paydown. For Elanco UK, Aqua was a relatively small business unit and has resulted in a reduction in annualised revenues of approximately £6.5m.”
- “In November 2024, the Company acquired a manufacturing facility in Speke, Liverpool which was owned and operated by a third party contract manufacturer until its administration in the 2nd half of 2024... result[ing] in our decision to acquire this manufacturing facility, safeguarding product supply and the employment of approximately 260 people...”
- “Under the UK Emissions Trading Scheme Order, the Company's Speke facility... had a failure to acquire and surrender credits... resulting in an outstanding liability to the Environment Agency (EA)... The legal basis for such a transfer is highly uncertain. The Company is cooperating with the EA... to demonstrate that it should not be held liable for costs incurred before the acquisition date.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 4 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| DAVIS, Nicholas | Director | 2025-04-01 | Jun 1975 | British |
| FROST, Matthew Jonathan | Director | 2021-07-01 | Jul 1972 | British |
| LEWIS, Christopher | Director | 2018-06-20 | Aug 1978 | British |
Show 4 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| AMBANI, Nilesh (Neel) Sukumar | Director | 2018-05-23 | 2018-12-07 |
| HUNT, Kristina Mary | Director | 2018-12-07 | 2026-01-23 |
| TROUTT, Peter | Director | 2018-06-20 | 2021-12-03 |
| VANHERSECKE, Francois Jean-Noel Emile | Director | 2019-09-05 | 2021-06-30 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Elanco Europe Gmbh | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors, Significant influence (as firm) | 2019-03-11 | Ceased 2019-03-11 |
| Elanco Animal Health Inc. | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2019-03-11 | Active |
| Eli Lilly And Company Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2018-05-23 | Ceased 2019-03-11 |
Filing timeline
Last 20 of 43 total filings
Material constitutional events — rename, articles re-file, resolution
- 2022-07-06 RESOLUTIONS Resolution
- 2022-07-06 MA Memorandum articles
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-01-29 | TM01 | officers | Termination director company with name termination date | |
| 2025-11-07 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2025-08-21 | AA | accounts | Accounts with accounts type full | |
| 2025-06-03 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-05-22 | AP01 | officers | Appoint person director company with name date | |
| 2024-09-18 | MR05 | mortgage | Mortgage charge part release with charge number | |
| 2024-09-10 | AA | accounts | Accounts with accounts type full | |
| 2024-07-23 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2024-06-05 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-10-09 | AA | accounts | Accounts with accounts type full | |
| 2023-09-20 | PSC02 | persons-with-significant-control | Notification of a person with significant control | |
| 2023-09-20 | PSC07 | persons-with-significant-control | Cessation of a person with significant control | |
| 2023-06-01 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-10-07 | AA | accounts | Accounts with accounts type full | |
| 2022-07-06 | RESOLUTIONS | resolution | Resolution | |
| 2022-07-06 | MA | incorporation | Memorandum articles | |
| 2022-06-16 | CH01 | officers | Change person director company with change date | |
| 2022-05-26 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-01-05 | AA | accounts | Accounts with accounts type full | |
| 2021-12-03 | TM01 | officers | Termination director company with name termination date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 3
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.